This section of pediculosis.com is devoted to news about corporate developments and company announcements.
TyraTech has reported an increase of 31% in sales during the first half of 2016.
Hatchtech is submitting its Xeglyze lice treatment to the FDA for approval and has signed a commercialisation agreement with Dr. Reddy’s.
Eden Research PLC has agreed a licensing deal with TerpeneTech Ltd granting exclusive use of its encapsulation technologies and other intellectual property for head lice treatments.
Tyratech have announced increased revenues for 2014, and are focussing more of their funding on Vamousse.
The patents concern methods for lice eradication via localised heat treatment, and are held by the University of Utah Research Federation, who have licensed them to Larada Sciences.
Larada Sciences developed AirAllé, a device for treating lice infection via heat treatment, which received FDA clearance in prior to its release with AirAllé branding in 2013.
Tyratech, Inc. has recently announced two further US distribution agreements for Vamousse, its lice treatment product.
Hatchtech recently announced plans to commercialise its Xeglyze lice treatment product, while Ego Pharmaceuticals expand their international distribution network.
Several head lice companies have recently released financial updates related to their head lice treatments.
Tyratech have announced increased sales for the Vamousse head lice treatment, and are extending their distribution network in both the US and the UK.
Two companies producing market-leading head lice products have released recent trading updates.